Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ACA
ACA logo

ACA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Arcosa Inc (ACA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
135.840
1 Day change
2.04%
52 Week Range
137.760
Analysis Updated At
2026/06/18
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Arcosa Inc (ACA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company is positioned for secular growth in infrastructure and electrification, supported by strong analyst ratings, bullish technical indicators, and positive sentiment in options data.

Technical Analysis

The MACD is positive and expanding (0.945), RSI indicates no overbought or oversold conditions (77.513), and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 135.406, R2: 139.325), suggesting upward momentum.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
10

Positive Catalysts

  • Strong analyst ratings with upward price target revisions (e.g., $140 from Barclays, $150 from Oppenheimer), secular growth trends in infrastructure and electrification, and improving profitability in aggregates.

Neutral/Negative Catalysts

  • No significant hedge fund or insider trading trends. Lack of recent news or congress trading data.

Financial Performance

No financial data available for the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are bullish on ACA, with multiple 'Buy' or 'Outperform' ratings and price targets ranging from $125 to $150, citing strong growth potential in infrastructure and electrification trends.

Wall Street analysts forecast ACA stock price to fall
1 Analyst Rating
Wall Street analysts forecast ACA stock price to fall
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 133.130
sliders
Low
115
Averages
115
High
115
Current: 133.130
sliders
Low
115
Averages
115
High
115
Oppenheimer
initiated
$150
AI Analysis
2026-05-28
Reason
Oppenheimer
Price Target
$150
AI Analysis
2026-05-28
initiated
Reason
Oppenheimer assumed coverage of Arcosa with an Outperform rating and $150 price target. The firm sees a constructive environment for the infrastructure services and products sector. \"Profound\" growth and planning for data centers and complex facilities, along with broader electrification trends, are putting upward pressure on multi-year infrastructure capital plans, the analyst tells investors in a research note.
Barclays
Adam Seiden
NULL
to
Overweight
maintain
$115 -> $140
2026-05-04
Reason
Barclays
Adam Seiden
Price Target
$115 -> $140
2026-05-04
maintain
NULL
to
Overweight
Reason
Barclays analyst Adam Seiden raised the firm's price target on Arcosa to $140 from $115 and keeps an Overweight rating on the shares. The firm views the company's Q1 report as strong. Arcosa is seeing secular growth in utilities, improving profitability in aggregates, and "disciplined" capital allocation, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ACA
Unlock Now

People Also Watch